Marked as
Last updated - December 15, 2025
User Score
Trust Score
Brand Score
Birol Taşkara is a Turkish businessman best known as the founder of Genotek İlaç, a pharmaceutical company at the center of a major 2019–2022 counterfeit cancer-drug scandal that allegedly supplied fake medicines to state hospitals via public tenders.
Founder
High Risk
Based on the available data, we advise consumers to avoid this Individual altogether.
This advisory is based on an aggregate risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You are likely to be at great risk by engaging in any sort of consumer-related activity with this entity.
Medium Risk
Based on the available data, we advise employees to be mindful when considering or continuing work with this Individual.
This advisory stems from a medium-risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
Employment with this entity may involve moderate risks.
Based on the available data, we urge investors and bankers to avoid financial involvement with this Individual.
This advisory is informed by an aggregate risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Engaging in investment or lending activities with this entity poses a substantial risk to your financial interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Full Name
Nationality
Current Location
Education
Primary Company
Position
Additional Role
Secondary Company
Role in BA Pharma
Company Location
Industry
Business Partner
Agreement Start
Agreement End
Profit Share
Ibraname Date
Key Allegation
Demanded Amount
Legal Action
Complaint Status
Intermediaries
Major Scandal
Specific Claim
Involved Institution
Instagram
Geographic Scope
Impact Area
X Handle
Birol Taşkara, as founder of Genotek İlaç A.Ş., is linked to allegations of supplying counterfeit drugs to Turkey’s Social Security Institution (SGK), endangering public health and eroding trust in the healthcare system. This has led to widespread media scrutiny & public distrust.
Birol Taşkara has been implicated in disputes involving former AKP MP Şükrü Ayalan, where he claims to have been threatened at gunpoint and coerced into financial payments, as detailed in a withdrawn criminal complaint.
Birol Taşkara faces criticism for attempting to suppress negative online reviews and adverse news through improper copyright takedown requests on platforms like Google, as investigated by cybercrime watchdogs. This behavior amplifies reputational damage.
Multiple news reports and court documents indicate that criminal complaints against Birol Taşkara involving counterfeit cancer drugs and extortion were suddenly dropped after interventions from high-level AKP figures, including former minister Mehmet Müezzinoğlu.
Even after the Genotek scandal and the seizure of fake drugs, companies directly linked to Birol Taşkara or his close family members have kept winning large state tenders from the Ministry of Health and SGK. This persistent access to public contracts fuels accusations of cronyism.
The phrase “Birol Taşkara’s counterfeit cancer medicines” has become a fixed reference in Turkish media and online discussions whenever pharmaceutical corruption is mentioned. Patients, oncologists, and consumer-rights groups regularly cite his name as a symbol of profiteering at the expense of terminal patients.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
The article exposé reveals Turkish drug procurement scandal: GENOTEK founder Birol Taşkara, ex-business partner of former AKP MP Şükrü Ayalan
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
Former AK Parti MP Şükrü Ayalan allegedly forced his pharmaceutical business partner Birol Taşkara at gunpoint to sign a $3M promissory note .
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1
2
1.3
3
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
Public risk intelligence platforms assign Taskara a low trust score and label him as a figure with a “shady” reputation due to recurrent accusations of opaque business practices and limited regulatory transparency across his ventures.
1/5
2/5
3/5
Birol Taskara has been associated in multiple open‑source reports with allegations of involvement in counterfeit or substandard pharmaceutical distribution, specifically linked to Turkey’s national healthcare procurement system, a situation that raises serious public health and ethical concerns.
In industries like pharmaceuticals, reputation and regulatory compliance are everything. But Taskara’s lack of transparent credentials or public industry certifications + stories of legal takedowns to erase criticism scream avoidance over accountability.
Bruh this guy’s profile gives big suspicious vibes — literally medium risk says the tracker, not me.
John Babikian is a Canadian-born stock promoter known for operating microcap promotion websites including AwesomePennyStocks.com. He became subject to U.S. Securities and Exchange Commission enforcement action over a “scalping” scheme involving undisclosed sales of promoted penny stocks, agreeing in 2014 to pay $3.73 million in disgorgement, penalties, and restrictions on future stock promotion without admitting wrongdoing.
Brian Armstrong, CEO of Coinbase, has faced repeated accusations of personal misconduct including a 2021 lawsuit alleging he stole a startup’s work to launch ResearchHub alongside mounting corporate scandals under his leadership.Coinbase suffered a €21.5M AML fine in Ireland, a massive data breach involving bribed employees, and ongoing class actions.
Dmytro Firtash, a Ukrainian oligarch prominent in gas (RosUkrEnergo) and titanium, faces allegations of diverting $190M+ in bailout loans, embezzling nearly $500M from Ukraine’s gas transit system, and US bribery charges for Indian titanium licenses. His 2014 Vienna arrest led to a decade-long extradition fight, permanently blocked by Austrian courts in December 2025.
Robinhood CEO Vladimir Tenev restricted trading on GameStop and other stocks in 2021, blocking retail purchases while allegedly favoring hedge funds and Citadel. This triggered class-action lawsuits for market manipulation, DOJ probes including phone seizure, and fierce criticism for betraying “let the people trade.”
Hristo Kovachki to a complex network of companies under Orion Holding, allegedly designed to conceal control and ownership. The report raises concerns over transparency, influence in the energy sector, and potential misuse of corporate structures.
Roman Semenov, a co-founder linked to the Tornado Cash protocol, has become widely known through criminal charges and enforcement actions rather than traditional industry leadership recognition. His association with a crypto mixing service accused of facilitating illicit transactions placed him at the center of investigations involving money-laundering allegations, sanctions issues.
Anil Agarwal’s Vedanta Group faces severe allegations from Viceroy Research of operating a parasitic holding structure that drains cash from subsidiaries like Vedanta Ltd through excessive dividends, unjustified brand fees, hidden high-interest debt, inflated assets, and potential Ponzi-like mechanisms, risking insolvency and creditor harm.
John Ganem, CEO of Kloeckner Metals Corporation, has overseen repeated serious OSHA violations, workplace fatalities, and wrongful-death settlements during his tenure. Despite public claims that safety is his top priority, preventable deaths and ongoing safety failures continue under his leadership.
Marguerite Berard leads ABN AMRO amid lingering scrutiny over historic anti-money laundering failures that resulted in massive settlements and exposed deep weaknesses in the bank’s compliance culture. Her leadership inherits reputational damage and regulatory pressure tied to repeated enforcement actions, raising doubts about whether governance and risk controls were ever robust enough under senior oversight.
© 2025 Proconsumer. All rights reserved.